Literature DB >> 18829539

Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.

Mandy J Binning1, Toba Niazi, Carolyn A Pedone, Bachchu Lal, Charles G Eberhart, K Jin Kim, John Laterra, Daniel W Fults.   

Abstract

Medulloblastomas are malignant brain tumors that arise by transformation of neural progenitor cells in the cerebellum in children. Treatment-related neurotoxicity has created a critical need to identify signaling molecules that can be targeted therapeutically to maximize tumor growth suppression and minimize collateral neurologic injury. In genetically engineered mice, activation of Sonic Hedgehog (Shh) signaling in neural stem cells in the developing cerebellum induces medulloblastomas. Hepatocyte growth factor (HGF) and its cell surface receptor c-Met are highly expressed in human medulloblastomas, and elevated levels of c-Met and HGF mRNA predict an unfavorable prognosis for patients. HGF is neuroprotective for cerebellar granule cells and promotes growth of human medulloblastoma cells in culture and in murine xenografts. We modeled the ability of HGF to induce medulloblastomas in mice using a version of the RCAS/tv-a system that allows gene transfer to cerebellar neural progenitors during their postnatal expansion phase when these cells are highly susceptible to transformation. Here, we report a high frequency of medulloblastoma formation in mice after postnatal expression of HGF in cooperation with Shh. Some tumors showed neurocytic differentiation similar to that in human nodular medulloblastomas with activated Shh signaling. Systemic administration of a monoclonal antibody against HGF prolonged survival of mice bearing Shh + HGF-induced medulloblastomas by stimulating apoptosis. These findings indicate a role for HGF in medulloblastoma initiation and growth and show efficacy of HGF-targeted therapy in a mouse model of endogenously arising tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829539      PMCID: PMC2638505          DOI: 10.1158/0008-5472.CAN-08-1899

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Prediction of central nervous system embryonal tumour outcome based on gene expression.

Authors:  Scott L Pomeroy; Pablo Tamayo; Michelle Gaasenbeek; Lisa M Sturla; Michael Angelo; Margaret E McLaughlin; John Y H Kim; Liliana C Goumnerova; Peter M Black; Ching Lau; Jeffrey C Allen; David Zagzag; James M Olson; Tom Curran; Cynthia Wetmore; Jaclyn A Biegel; Tomaso Poggio; Shayan Mukherjee; Ryan Rifkin; Andrea Califano; Gustavo Stolovitzky; David N Louis; Jill P Mesirov; Eric S Lander; Todd R Golub
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

2.  Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.

Authors:  B Cao; Y Su; M Oskarsson; P Zhao; E J Kort; R J Fisher; L M Wang; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

3.  Medulloblastoma with extensive nodularity: a variant with favorable prognosis.

Authors:  F Giangaspero; G Perilongo; M P Fondelli; M Brisigotti; C Carollo; R Burnelli; P C Burger; M L Garrè
Journal:  J Neurosurg       Date:  1999-12       Impact factor: 5.115

4.  In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.

Authors:  Roger Abounader; Bachchu Lal; Carey Luddy; Gary Koe; Beverly Davidson; Eliot M Rosen; John Laterra
Journal:  FASEB J       Date:  2001-11-29       Impact factor: 5.191

5.  Apoptosis, neuronal maturation, and neurotrophin expression within medulloblastoma nodules.

Authors:  C G Eberhart; W E Kaufman; T Tihan; P C Burger
Journal:  J Neuropathol Exp Neurol       Date:  2001-05       Impact factor: 3.685

6.  Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.

Authors:  C Wetmore; D E Eberhart; T Curran
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

7.  Met and hepatocyte growth factor/scatter factor expression in human gliomas.

Authors:  S Koochekpour; M Jeffers; S Rulong; G Taylor; E Klineberg; E A Hudson; J H Resau; G F Vande Woude
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

8.  Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.

Authors:  D Tomioka; N Maehara; K Kuba; K Mizumoto; M Tanaka; K Matsumoto; T Nakamura
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

9.  Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/akt-dependent and MAPK/CREB-independent.

Authors:  Mir Ahamed Hossain; Juliet C Russell; Raquel Gomez; John Laterra; Raquel Gomes
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

10.  Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.

Authors:  R Wang; L D Ferrell; S Faouzi; J J Maher; J M Bishop
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

View more
  18 in total

1.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 2.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

Review 3.  Matching mice to malignancy: molecular subgroups and models of medulloblastoma.

Authors:  Jasmine Lau; Christin Schmidt; Shirley L Markant; Michael D Taylor; Robert J Wechsler-Reya; William A Weiss
Journal:  Childs Nerv Syst       Date:  2012-04       Impact factor: 1.475

4.  Functional genomics identifies drivers of medulloblastoma dissemination.

Authors:  Michael Mumert; Adrian Dubuc; Xiaochong Wu; Paul A Northcott; Steven S Chin; Carolyn A Pedone; Michael D Taylor; Daniel W Fults
Journal:  Cancer Res       Date:  2012-08-08       Impact factor: 12.701

5.  WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma.

Authors:  Tiffany A Doucette; Yuhui Yang; Carolyn Pedone; John Y H Kim; Adrian Dubuc; Paul D Northcott; Michael D Taylor; Daniel W Fults; Ganesh Rao
Journal:  Neurosurgery       Date:  2012-04       Impact factor: 4.654

6.  PTEN reconstitution alters glioma responses to c-Met pathway inhibition.

Authors:  C Rory Goodwin; Bachchu Lal; Sandra Ho; Crystal L Woodard; Xin Zhou; Alexandra Taeger; Shuli Xia; John Laterra
Journal:  Anticancer Drugs       Date:  2011-10       Impact factor: 2.248

7.  Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma.

Authors:  Paul N Kongkham; Sara Onvani; Christian A Smith; James T Rutka
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

8.  Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model.

Authors:  Tiffany Doucette; Ganesh Rao; Yuhui Yang; Joy Gumin; Naoki Shinojima; B Nebiyou Bekele; Wei Qiao; Wei Zhang; Frederick F Lang
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

9.  Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma.

Authors:  Robert C Castellino; Benjamin G Barwick; Matthew Schniederjan; Meghan C Buss; Oren Becher; Dolores Hambardzumyan; Tobey J Macdonald; Daniel J Brat; Donald L Durden
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

Review 10.  Brain tumor stem cells.

Authors:  Zhigang Xie
Journal:  Neurochem Res       Date:  2009-10-24       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.